Karolinska Development Put To The Test
This article was originally published in Start Up
Sweden’s publicly traded Karolinska Development AB has turned a close relationship with one of Europe’s top biomedical research institutions into an investment portfolio of two dozen biotech assets, all built as virtual companies. It’s a twist on the asset financing model that’s gaining attention among biopharma VCs, but KD needs a sale or two soon to make its version work.
You may also be interested in...
In our second annual Life Science VC Survey, biopharma investors continue to look to oncology and rare disease, while their cold shoulder toward metabolic disease seems to be warming. Even though most agree the traditional biotech funding model is broken, our participants are far from convinced that new models such as asset-based financing are the answer.
In our second annual Life Science Venture Survey, VCs paid their respects to the importance of corporate investors right now. For their part, corporate investors, many from long-established programs, said they are bullish about making more bets in early-stage companies.
Lilly and Canadian VCs back a new TVM Life Sciences fund that will invest in a network of single-asset companies in Quebec.